Solera Health Adds Noom to Its Curated Weight Management Network

Solera Health is adding another name to its weight management roster. The digital health company announced Sept. 1 that it has struck a partnership with Noom, bringing two of Noom's flagship offerings, Noom Weight and its Diabetes Prevention Program, into Solera's network of curated vendors.

The mechanics matter here more than the headline. Noom Weight functions as a GLP-1 companion program, designed to support members who are already on weight-loss drugs like semaglutide or tirzepatide. The DPP carries CDC Full Plus recognition, a designation that signals rigor in outcomes reporting. Noom will also layer in a GLP-1 companion offering at no added cost to members, according to the announcement.

Kris Heinzen, Solera's chief product officer, framed the deal as a validation of Noom's evidence base rather than a simple expansion for its own sake. "Every addition to our network must clear a high bar, and Noom has done so with its strength of evidence," Heinzen said in a statement. He pointed to the network's design philosophy: matching the right program to the right person without forcing health plans and employers to onboard yet another standalone vendor. "That's the whole premise of our curated network: choice without complexity," he said.

Why the Numbers Matter

Noom brings data that's hard to ignore. The company reports that 82% of Noom Weight members lost 5% or more of their body weight within a year. On the diabetes side, 64% of DPP participants prevented or delayed the onset of Type 2 diabetes. Those are not marginal figures in a category where adherence and long-term efficacy have historically been weak points for digital weight-loss offerings.

The cost argument is where this gets interesting for plan sponsors. Noom claims its two programs save members between $1,219 and $5,341 annually in healthcare costs. That's a wide range, and the variance likely reflects differences in baseline risk between the DPP population and the broader GLP-1 companion cohort. Still, even the low end of that range is a meaningful number when multiplied across a large employer's covered population.

Cody Fair, Noom's chief commercial officer, leaned into the same vendor-fatigue argument Heinzen made. "Health plans and employers want proven results without adding another vendor to manage, and that's exactly what Solera's network delivers," Fair said. He added that sitting alongside a CDC-recognized DPP and a no-cost GLP-1 companion means members get "evidence-based support exactly when they need it, whether they're managing their weight, preventing diabetes, or navigating a GLP-1 prescription."

This is not Noom's first foray into adjacent health monitoring. The company recently launched an at-home biomarker test kit aimed at metabolic health tracking, a move that suggests Noom is trying to build a broader data layer around its behavioral coaching model rather than remain a single-purpose weight-loss app. Pairing that kind of biomarker data with GLP-1 companion coaching could, in theory, give Noom a differentiated position as GLP-1 drugs become a larger share of employer pharmacy spend.

Why It Matters

The GLP-1 companion category has become crowded fast. Pharmacy benefit managers and self-insured employers are grappling with the cost of covering drugs like Ozempic and Zepbound, and every vendor in this space is racing to prove it can extend or amplify drug efficacy while managing total cost of care. Solera's pitch is not that any single program wins that race. It's that a curated network, one that vets and layers multiple vendors under a single point of access, solves the operational headache that comes with plan sponsors trying to manage five or six point solutions independently.

That's a real problem in enterprise health benefits. Point-solution fatigue is well documented among employers who have added digital health vendors over the past several years only to find utilization low and administrative overhead high. Solera's model, aggregating vetted programs like Betr, Transform, Weight Watchers and Modify Health alongside Noom, is a bet that aggregation itself is the value proposition, not any single program's outcomes data.

The risk for Solera is that this model depends heavily on the strength of its underlying partners. If Noom's outcomes data doesn't hold up in real-world deployment at scale, or if member engagement drops off after the initial enrollment period, as often happens with digital health interventions, the network's credibility takes the hit alongside Noom's. Solera is effectively underwriting quality control for every program it adds, which raises the stakes on due diligence claims like Heinzen's "high bar."

For Noom, the calculus is different. Distribution through Solera's existing employer and health plan relationships likely matters more than the direct commercial terms of this specific deal. Digital health vendors have learned the hard way that direct-to-employer sales cycles are long and expensive. Riding inside an established network shortens that cycle considerably, even if it means sharing margin or ceding some control over positioning.

The Bottom Line

This deal is less about Noom's product mechanics and more about distribution economics in a saturated digital health market. The 82% weight-loss success rate and $1,219 to $5,341 in claimed annual savings are compelling numbers on paper, but the real test will be whether Solera's aggregation model actually reduces employer churn and improves member engagement compared to standalone vendor relationships. Watch utilization data over the next two to three enrollment cycles. That's where this partnership either proves the curated-network thesis or becomes one more entry in a crowded, unproven category.